ReviewCurrent opinion in virology2017
Vaccination strategies against Zika virus.
Review in Current opinion in virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- The worldwide seroprevalence of DENV, CHIKV and ZIKV infection: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2021Pooled it
- A Zika virus vaccine with E protein fusion loop mutations protects via CD8Nature microbiology · 2026Article
- Review
- The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections.Clinical microbiology reviews · 2023Review
- Emerging trends of research on mRNA vaccines: A co-citation analysis.Human vaccines & immunotherapeutics · 2022Article
- Zika M-A Potential Viroporin: Mutational Study and Drug Repurposing.Biomedicines · 2022Article
- Host immune response against DENV and ZIKV infections.Frontiers in cellular and infection microbiology · 2022Review
- A modified age-structured SIR model for COVID-19 type viruses.Scientific reports · 2021Article
- Construction of a recombinant avipoxvirus expressing the env gene of Zika virus as a novel putative preventive vaccine.Virology journal · 2021Article
- A review on Zika virus outbreak, epidemiology, transmission and infection dynamics.Journal of biological research (Thessalonike, Greece) · 2020Review
- Immune Reactivity of a 20-mer Peptide Representing the Zika E Glycan Loop Involves the Antigenic Determinants E-152/156/158.Viruses · 2020Article
- Lipid Nanoparticle Formulation Increases Efficiency of DNA-Vectored Vaccines/Immunoprophylaxis in Animals Including Transchromosomic Bovines.Scientific reports · 2020Article
- A new class of broadly neutralizing antibodies that target the glycan loop of Zika virus envelope protein.Cell discovery · 2020Article
- Host and viral mechanisms of congenital Zika syndrome.Virulence · 2019Review
- Identification of potential Zika virus NS2B-NS3 protease inhibitors via docking, molecular dynamics and consensus scoring-based virtual screening.Journal of molecular modeling · 2019Article
- Identification of relevant regions on structural and nonstructural proteins ofNew microbes and new infections · 2019Article
- Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development.Frontiers in immunology · 2019Review
- Zika virus: epidemiology, clinical aspects, diagnosis, and control of infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Review
- Animal Models of Zika Virus Infection during Pregnancy.Viruses · 2018Review
- Zika virus vaccines: immune response, current status, and future challenges.Current opinion in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The epidemic emergence of Zika virus (ZIKV) in 2015-2016 has been associated with congenital malformations and neurological sequela. Current efforts to develop a ZIKV vaccine build on technologies that successfully reduced infection or disease burden against closely related flaviviruses or other RNA viruses. Subunit-based (DNA plasmid and modified mRNA), viral vectored (adeno- and measles viruses) and inactivated viral vaccines are already advancing to clinical trials in humans after successful mouse and non-human primate studies. Among the greatest challenges for the rapid implementation of immunogenic and protective ZIKV vaccines will be addressing the potential for exacerbating Dengue virus infection or causing Guillain-Barré syndrome through production of cross-reactive immunity targeting related viral or host proteins. Here, we review vaccine strategies under development for ZIKV and the issues surrounding their usage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.